ArticleHealth science reports2025
Association of Long-Term Oral β-Blocker Use With Cardiac Troponin I and B-Type Natriuretic Peptide in Septic Myocardial Injury: A Retrospective Cohort Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploration and prospect of core research hotspots in sepsis-induced myocardial injury based on bibliometrics.Medicine · 2026Article
- Association of Long-Term Oral β-Blocker Use With Cardiac Troponin I and B-Type Natriuretic Peptide in Septic Myocardial Injury: A Retrospective Cohort Study.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Septic myocardial injury, characterized by elevated levels of cardiac troponin I (cTnI) and B-type natriuretic peptide (BNP), is associated with increased mortality in sepsis. This study aimed to evaluate whether chronic oral β-blocker use is associated with reduced cardiac biomarker levels and improved short-term outcomes. Methods: We conducted a retrospective cohort study of 289 patients diagnosed with septic myocardial injury admitted to the ICU/EICU from January 2015 to June 2020. Patients were stratified into chronic β-blocker users ( Results: Chronic β-blocker use was independently associated with significantly lower serum levels of cTnI (0.19 vs. 0.29 μg/L; Conclusion: Long-term β-blocker therapy is associated with lower levels of cardiac injury biomarkers in patients with septic myocardial injury. Subgroup analyses revealed greater reductions in younger patients and those with pulmonary infections, though these findings are exploratory. However, these biochemical improvements did not translate into short-term survival benefits. Prospective trials are needed to determine whether myocardial protection translates into clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.